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Introduction
Lynch syndrome (LS), formerly known as hereditary 
nonpolyposis colorectal cancer, is the most common form 
of hereditary colorectal cancers (Lynch et al., 2006). LS 
is clinically defined as an autosomal dominantly inherited 
multicancer condition (Zeinalian et al., 2015b) and 
characterized by germ line mutation in genes responsible 
for DNA mismatch repair (MMR): MLH1, MSH2, MSH6, 
MSH3, and PMS2 (Boland, 2013) (Table 1). 
In 1993 it was found that loss of MMR function lead 
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Abstract
 Background: Colorectal malignancies with high microsatellite instability (MSI-H), either hereditary  (Lynch 
syndrome) or sporadic, demonstrate better prognosis and altered response to 5FU chemotherapy. It is now 
recommended to perform MSI testing for all new cases of colorectal cancer regardless of being categorized 
as hereditary or sporadic. For MSI detection, immunohistochemistry or PCR-based protocols using a cohort 
of various sets of STR markers are recommended. Here we aimed to evaluate a simplified protocol using just 
a single STR marker, MT1XT20 mononucleotide repeat, for detection of MSI in Lynch syndrome patients. A 
Promega five-marker MSI testing panel and immunohistochemistry (IHC) were used as the gold standard in 
conjunction with MT1XT20. Materials and Methods: Colorectal patients with a positive history of familial cancers 
were selected by evaluating medical records. Based on Amsterdam II criteria for Lynch syndrome 20 families 
were short listed. DNA was extracted from formalin fixed paraffin embedded tumour and adjacent normal 
tissues resected from the index case in each family. Extracted DNA was subjected to MT1XT20 mononucleotide 
marker analysis and assessment with a commercially available five marker MSI testing kit (Promega, USA). 
IHC also was performed on tissue sections and the results were compared with PCR based data. Results: Eight 
(40%), seven (35%) and five (25%) cases were MSI positive using with the Promega kit, IHC and MT1XT20, 
respectively. Among the markers included in Promega kit, BAT26 marker showed instability in all 8 samples. 
NR24 and NR21 markers showed instability in 7 (87.5%), and BAT25 and MONO 27 in 6 (75%) and 5 (62.5%). 
Conclusions: Although MT1XT20 was earlier reported as a valid standalone marker for MSI testing in CRC 
patients, we could not verify this in our Iranian patients. Instead BAT26 among the markers included in Promega 
MSI testing kit showed instability in all 8 MSI-H CRC samples. Therefore, it seems BAT26 could act well as a 
single marker for MSI testing in Iranian CRC patients. 
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to the phenomenon of microsatellite instability (MSI) in 
CRC tumors (Ionov et al., 1993; Thibodeau et al., 1996; 
Boland, 2013). Microsatellites are highly polymorphic, 
short, tandemly repeated nucleotide sequences of 1-6 
bases distributed throughout the human genome (Tautz, 
1989; Chaksangchaichot et al., 2007). In such tumor cells, 
typically half or more of all microsatellites demonstrate 
mutations, contraction or expansion (Shemirani et 
al., 2011). This phenotype, referred to as high-level 
microsatellite instability (MSI-H) tumor (Zeinalian et 
al., 2015a). So microsatellite instability (MSI) serves as 
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an excellent, easy to evaluate marker of mismatch repair 
deficiency in LS patients (Lynch and de la Chapelle, 2003). 
LS patients are at risk of developing frequent 
metachronous colon cancer (Fukutomi et al., 2002) or 
extra colonic tumors (including endometrium and, to a 
lesser extent, ovary, stomach, hepatobiliary tract, small 
bowel, pancreas, brain) and increased risk of cancer 
in family members (Lynch et al., 2006). In addition, 
colorectal malignancies demonstrating MSI, have a 
relatively favorable prognosis (Haghighi et al., 2009), 
altered response to 5-Fluorouracil (5FU) based adjuvant 
chemotherapy (Ribic et al., 2003; Deschoolmeester et al., 
2008) and altered operative treatment surgery approach 
(Rodriguez-Bigas and Möeslein, 2013). Several studies 
indicate that benefit from 5-FU adjuvant chemotherapy 
may be restricted to non MSI-H colorectal cancer patient 
(Ribic et al., 2003; Ng and Schrag, 2010; Tejpar et al., 
2011). 
Accordingly, identification of the MSI phenotype 
is an independent prognostic tool leading to a better 
management of LS and is extensively accepted as an 
standalone method for LS confirmation in suspected 
colorectal patients (Ward et al., 2002; Deschoolmeester 
et al., 2008; Shia, 2008; Rodriguez-Bigas and Möeslein, 
2013).
In 1997 the National Cancer Institute proposed a panel 
of five microsatellite markers for MSI detection including 
two mononucleotide repeats and three dinucleotide repeats 
known as the Bethesda panel (Boland et al., 1998). In 2004 
to improve the accuracy of MSI testing using the Bethesda 
panel of MSI markers, a panel of five mononucleotide 
markers (known as the Promega panel) was developed 
(Bacher et al., 2004). 
At present MSI testing offer to the CRC patients 
demonstrating Amsterdam and/or Bethesda criterion, 
usually using a recommended panel of five monomorphic 
markers. However, due to the laborious nature and high 
cost of multimarker MSI testing, efforts have been 
employed to find simpler alternatives with less number of 
markers (Patil et al., 2012). In order to develop an easier, 
cost effective and rapid method without compromising 
the sensitivity and specificity issues, various studies 
have performed to assess the reliability and accuracy of 
single mononucleotide repetitive markers for MSI testing 
(Buhard et al., 2006; Xicola et al., 2007; Deschoolmeester 
et al., 2008). 
In this study, we have evaluated the sensitivity and 
specificity of MT1XT20 mononucleotide marker for 
MSI testing in colorectal patients showed Amsterdam 
II criteria. The five markers Promega MSI testing 
commercial kit used as the gold standard. However, for the 
sake of comparison between PCR-based methods and IHC 
we have performed IHC detection of all four important 
MMR proteins as well.
Table 1. Genes Involved in HNPCCa
Gene name Bacterial 
homolog
Location Frequency of 
mutations
Function Interactions Involvement in other cancers
MSH2/HNPCC1 MutS 2p22 About 60% Mismatch recognition Heterodimerizes with 
MSH6 to form MutS 
alpha /
Turcot syndrome
Heterodimerizes with 
MSH3 to form MutS 
beta
Muir-Torre 
syndrome
MLH1/HNPCC2 MutL 3p21 About 30% Mediates protein-
protein interactions 
during mismatch 
recognition
Heterodimerizes with 
PMS2 to form MutL 
alpha
Turcot syndrome
Muir-Torre 
syndrome
MSH6/HNPCC5 mutS 2p16 About 7-10% Mismatch recognition Heterodimerizes with 
PMS2 to form MutS 
alpha
Turcot syndrome
Familial 
endometrial cancer
PMS2/HNPCC4 MutL 7p22 Rare Endonuclease Heterodimerizes with 
MLH1 to form MutL 
alpha
Turcot syndrome
PMS1/HNPCC3 MutL 2q31-q33 Case report Probably involved in 
the repair of mis-
matches
Heterodimerizes with 
MLH1
MLH3/HNPCC7 MutL 14q24.3 Under debate Redundant of PMS2 Heterodimerizes with 
MLH1 to form MutL 
alpha
Susceptibility to 
endometrial cancer
TGFBR2/HNPCC6 3p22 Case report Tumor suppressor Bins to another 
TGFBR2 and 2 
TGFBR1  to form 
receptor complex/ 
binds TGF-beta/
Somatic 
esophageal cancer
Loeys-Dietz 
syndrome type 2
EPCAM/TACSTD1/
HNPCC8
2P21 Rare 3' EPCAM deletions 
lead to MSH2 
promoter hyper-
methylation and 
inactivation
a www.omim.org
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Materials and Methods
Population study
The study was approved by Isfahan University 
of Medical Sciences Ethical Committee. The cancer 
registry of Poursina Hakim CRC clinical center with 
1659 registered cases was screened for selection of CRC 
patients with LS criteria like age of CRC onset below 50 
and occurrence of frequent CRC or other related cancers 
in his/her family members. All patients requested to fill 
up a structured questionnaire collecting all important data 
regarding their own and family history of CRC and other 
related cancers. Informed written consent was obtained 
from all individuals participated in the study. Among all 
1659 patients, 40 patients were selected with strict criteria 
of Amsterdam II. Eventually, on the basis of paired tissues 
availability (CRC resected tissue and its paired normal 
adjacent tissue) and the patients’ cooperation, 20 of them 
were selected for the present study. 
Genomic DNA extraction
Genomic DNA was purified from 20 CRC and 20 
adjacent normal formalin-fixed, paraffin-embedded 
(FFPE) tissues. Briefly, two 10 micrometer tissue slices 
placed in a clean 1.5 ml Eppendorf tube and incubated 
at room temperature for 15 minutes in 1 ml xylene for 
deparaffinization. Then the tubes were centrifuged at 
13000 RPM for 5 minutes. Rehydrated by stepwise 
passing through grades of absolute ethanol to 30% and 
then distilled water. After rehydration step, centrifugation 
and drain of supernatant, 600 microliters of 1% SDS, 
30 microliters of 20 mg/ml proteinase K and 20 beads 
of Chelex 20 were added to the samples and incubated 
overnight at 55 °C in a water. Centrifuged and supernatants 
were collected in a clean Eppendorf tube and subjected to 
phenol-chloroform extraction.
Multiplex PCR reactions for Promega MSI testing system
Promega MSI testing kit (MSI Analysis System, 
Version 1.2) included 5 quasi-monomorphic markers 
(NR-21, BAT-26, BAT-25, NR-24 and Mono-27) for 
MSI detection and two pentanucleotide markers (Penta C 
and Penta D) as sample detector to distinguish probable 
specimen mix-ups (Table 2). The multiplex PCR assay was 
carried out according to the manufacturer’s recommended 
protocol. Subsequently, PCR products were analyzed 
using an ABI PRISM 3100 Genetic Analyzer (Applied 
Biosystems) as recommended by Promega. The peaks 
were interpreted employing GeneMapper 3.7 software 
(Applied Biosystems). Any discrepancy between the 
number of alleles in tumor and its paired normal tissue was 
considered as instability in microsatellite repeat sequences. 
Specimens with more than two of five microsatellite 
markers alteration were considered as MSI-H, two or one 
altered microsatellite markers categorized as MSI low 
(MSI-L) and those without any microsatellites alteration 
considered as microsatellite stable (MSS). 
Mononucleotide marker assay
The amplification of MT1XT20 mononucleotide marker 
was carried out in a total volume of 25 µl consisted100 ng 
of tumor or normal tissue extracted DNA, 2.5 µl of 10X 
PCR buffer, 0.4 mM of each reverse and forward primers 
(Forward 5’-CAGCTGTGCTCTCAGATGTAAA-3’ and 
Reverse 5’-CCAAGTGCCATATACCCAGTGA-3’), 0.5 
Units of Taq polymerase enzyme, 0.2 mM of each dNTPs 
and 1.5 mM of MgCl2.
Tubes were then placed in an Eppendorf thermocycler 
(Germany) and subjected to following thermal cycling 
condition: initial denaturation at 95 C° for 5 minutes, 
followed by 30 cycles of 94°C, 58°C and 72°C all for 30 
seconds and 1 final extension cycle at 72°C for 10 minutes. 
The 5’ end of reverse PCR primer was fluorescently 
labeled with Cy5 fluorescent dye. PCR products then 
analyzed using Automated Laser Fluorescence Express 
(ALF express) sequencer and AlleleLinks software 
provided by the manufacturer.
IHC analysis
Tumor and paired normal specimens were prepared 
on at least 4 slides for IHC analysis. The expression 
assessment of MSH2, MLH1, MSH6 and PMS2 proteins 
was performed on 1-2 µm thick sections of formalin-fixed 
and paraffin-embedded tissues. After deparaffinization 
of sections in xylene and rehydration through graded 
alcohols, the antigen retrieval step was performed in a 
pressure chamber at microwave for 20 minutes using Tris-
EDTA, pH 9.0 buffer, then sections were washed in dH2O. 
In order to neutralize the endogenous peroxidase, the 
slides were incubated in hydrogen peroxide for at least 5 
minutes and were washed in PBS twice for 5 minutes each.
For blocking of non-specific background staining, each 
section were blocked by protein blocking solution for 5 
minutes. After washing the sections in PBS two times for 
5 minutes each, the primary diluted antibodies, including: 
NCL-MSH2, NCL-L-MLH1, NCL-L-MSH6 and NCL-
Table 2. The Promega Panel Mononucleotide Markers in Comparison with MT1XT20 Single Marker
Marker Gene GenBank 
number
Location Repeats Length Fluorescent dye
Number 
of stable 
samples
Number 
of instable 
samples
Promega markers:
BAT26 MSH2 U41210 Intron 5 26(T) 103-115 bps FAM/FL 12 8
NR24 ZNF2 X60152 3'UTR 24(T) 130-133 bps NED/TMR 13 7
NR21 SLC7A8 XM033393 5'UTR 21(T) 94-101 bps HEX/JOE 13 7
BAT25 c-Kit L04143 Intron 16 25(T) 114-124 bps HEX/JOE 14 6
MONO 27 MAP4K3 AC007684 5'UTR 27(T) 142-154 bps HEX/JOE 15 5
Single marker:
MT1XT20 MT1X KJ891650.1 3' UTR T20 185-190 bps Cy5 15 5
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L-PMS2 (Leica Biosystems), were added to each section 
and incubated overnight at 4°C.
The primary antibody solution was removed after 
twice washing the slides in PBS and followed by 30 
minutes incubation with Post Primary Block reagent. After 
washing twice in PBS, slides were incubated in Novolink 
Polymer for 30 minutes, washed and DAB substrate 
solution added. The process followed by counterstaining 
with hematoxylin and ultimately dehydration, clearing 
and mounting of slides. Evaluation of slides was made 
by an experienced pathologist and categorized as MMR-
proficient or MMR-deficient based on the presence or 
absence of MMR protein nuclear stains.
Statistical analysis
Sensitivity and specificity and positive predictive 
values of clinical parameters were analyzed using SPSS 
19 software package for Windows (SPSS Inc., Chicago, 
IL, USA). 
Results 
Cancer type, location, age and gender
In this study 20 CRC patients selected on the basis 
of Amsterdam II criteria for whom paraffin embedded 
and formalin fixed tissue blocks from already resected 
colon tumors were available. In family members of 
MMR-deficient and MSI-H cases, the following cancers 
were frequently detected: colorectal, gastric, small 
bowel, hematopoietic, prostate and breast (Table 3a). 
In these cases the most frequent tumor locations were 
ascending and descending colon (Table 4a). However, in 
family members of IHC-proficient or MSI-L/MSS cases 
gastric, lung and breast cancers was detected as the most 
frequent cancer types (Table 3b). The most common 
involved sites in this group of patients were sigmoid and 
rectum (Table 4b). The average age of MSI-H patients 
was 38.5 years at tumor diagnosis time (range 31 to 49), 
and that of MSI-L/MSS patients 46.5 years (range 24 to 
64). Most of MSI-H tumors, were detected as poorly or 
moderately differentiated adenocarcinoma, but there was 
no mucinous adenocarcinoma among these tumors. The 
most frequent tumor type among MSI-L/MSS patients was 
well differentiated adenocarcinoma (Table 5). 
Promega five markers MSI testing panel and MT1XT20 
single marker MSI analysis
Using Promega commercial MSI testing kit, 8 samples 
showed high instability in microsatellite markers (MSI-H) 
Figure 1. DNA Electropherograms of Promega 
MSI Analysis System (GeneMapper v3.7 Software), 
Indicating Stable Status of Both Normal and Tumoral 
Tissues and Unstable State of Tumoral Tissue 
Compared with Normal Paired Tissue
Table 4. Frequency of Tumor Sites in Iranian Colorectal 
Cancer Patients (A) MSI-H and MMR-Deficient 
Groups (B) MSS/MSI-L and MMR-Proficient Groups
A
Cancer Location
MSI-H Cases MMR-deficient 
Cases
Frequency Percent Frequency Percent
Cecum 1 12.5 1 14.2
Ascending colon 2 25 2 28.5
Transverse colon 1 12.5 1 14.2
Descending 
colon
2 25 2 28.5
Sigmoid colon 1 12.5 1 14.2
Rectum 1 12.5 0 0
Unknown 0 0 0 0
Total 8 100 7 100
B
Cancer Location MSS/MSI-L Cases
MMR-proficient 
Cases
Frequency Percent Frequency Percent
Cecum 1 8.3 1 7.6
Ascending colon 0 0 0 0
Transverse colon 0 0 0 0
Descending 
colon
0 0 0 0
Sigmoid colon 6 50 6 46.1
Rectum 4 33.3 5 38.4
Unknown 1 8.3 1 7.6
Total 12 100 13 100
Table 3. Frequencies of Cancer Locations among 
Iranian Colorectal Cancer Families (A) MSI-H and 
MMR-Deficient Groups. (B) MSS/MSI-L and MMR-
Proficient Groups
A
Cancer Type
MSI-H Families MMR-deficient  
Families
Frequency Percent Frequency Percent
CRC 28 65.1 27 64.2
Small Bowel 3 7 2 4.7
Hematopoietic 3 7 3 7.1
GC 2 4.6 4 9.5
Breast 2 4.6 1 2.3
Prostate 2 4.6 2 4.7
Lung 1 2.3 1 2.3
Other 2 4.6 2 4.7
Total 43 100 42 100
B
Cancer Type
MSS/MSI-L Families
MMR-proficient 
Families
Frequency Percent Frequency Percent
CRC 22 33.3 23 34.3
Small Bowel 3 4.5 4 5.9
Hematopoietic 1 1.5 1 1.4
GC 10 15.1 8 11.9
Breast 5 7.5 6 8.9
Prostate 3 4.5 3 4.47
Lung 6 9 6 8.9
Other 16 24.2 16 23.8
Total 66 100 67 100
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Table 6. Comparison between (a) MSI Analysis by 
Promega kit and IHC Results (b) MSI Analysis by 
MT1XT20 marker and IHC Results (c) MSI Analysis 
by Promega kit and by MT1XT20 Marker Results
a IHC Analysis
MSI analysis by 
Promega kit
MMR-
proficient  
MMR-deficient 
8 MSI-H cases 2 6
12 MSS/MSI-L cases 11 1
b IHC Analysis
MSI analysis by 
MT1XT20 marker
MMR-
proficient  
MMR-deficient 
5 microsatellite instable 
cases
2 3
15 microsatellite stable 
cases
11 4
c MSI analysis by MT1XT20 marker
MSI analysis by 
Promega kit
Microsatellite 
instable cases
Microsatellite 
stable cases
8 MSI-H cases 5 3
12 MSS/MSI-L cases 0 12
Table 5. Frequency of Tumor Phenotypes in Iranian 
Colorectal Cancer Patients at Risk for LS in both 
MSI-H and MSS/MSI-L Families
Tumor Grading
MSI-H Cases MSI-L/MSS Cases
Frequency Percent Frequency Percent
Well differentiated 
adenocarcinoma 2 25 5 41.6
Poorly 
differentiated 
adenocarcinoma
3 37.5 3 25
Moderately 
differentiated 
adenocarcinoma
3 37.5 3 25
Unknown 0 0 1 8.3
Total 8 100 12 100
(40%) and 12 samples showed low instability or stable 
status (60%). Female to male proportion in MSI-H 
cases was 4/4=1 and in MSI-L/MSS was 8/4=2. Among 
5 quasimononucleotide markers included in Promega 
kit, BAT26 marker with instability in all 8 samples was 
the most instable marker (40%). Both NR24 and NR21 
markers showed instability in 7 cases (35%), BAT25 and 
MONO 27 markers were instable in 6 (30%) and 5 (25%) 
specimens respectively (Figure 1)
For MT1XT20 quasimonomorphic marker size shift 
of tumoral sample in comparison to its adjacent normal 
tissue was considered for categorization of the samples 
as MSI-H or MSS. Figure 2 shows an example of instable 
repeats for MT1XT20 marker in tumoral and normal 
samples. Four alleles were detected for MT1XT20 marker 
in our study population ranging from 185 to 190 bps. 
Five samples were detected as MSI-H using MT1XT20 
as standalone marker.
IHC staining
Seven cases (35%) showed lack of expression 
(abnormal staining) of at least one of the MMR proteins in 
their tumor specimens (designated as IHC-A for absence 
of one or more MMR proteins). The remaining 13 cases 
were detected with no defects in any one of the MMR 
proteins (IHC-P or IHC-present group). Among the 7 
IHC-absent cases, 4 samples showed negative staining 
for either MLH1 and PMS2 proteins (57 %), 2 samples 
were negative for MSH2 and MSH6 (28.5%) and the 
remaining one sample showed loss of MSH6 protein 
expression (14%). 
Diagnostic sensitivity and specificity evaluation and 
positive predictive values
MT1XT20 marker showed 62.5% sensitivity and 100% 
specificity. Positive predictive values (PPV) for MT1XT20 
marker was 100%. The sensitivity and specificity of the 
IHC staining method was 75% and 91.67% respectively 
with PPV of 85.71% (Table 6).
Discussion
The annual occurrence of colon and rectum cancers 
is 6–7.9 per 100,000 in Iran, with approximately 4.7% 
of them diagnosed as LS (Nemati et al., 2012). About 
70-90% of LS patients show instability in microsatellite 
sequence repeats (Fishel, 1999). In LS one or more MMR 
genes (MLH1, MSH2, MSH6, and PMS2) undergo 
inactivation germ line mutation (Vatandoost et al., 2016). 
Some non-LS colorectal cancer also show MSI which 
is usually due to the MLH1 silencing because of its 
promoter hypermethylation. At present, the simultaneous 
implementation of both microsatellite instability analysis 
and IHC testing is highly sensitive and reliable screening 
method for LS diagnosis. IHC alone may not identify 
LS patients with frame shift mutations, splice site 
mutations and large genomic rearrangements, because the 
dysfunctional protein would still be observable with IHC 
staining (Boland et al., 1998; Shia, 2008). Alternatively 
MSI testing using PCR based methods is an indispensable 
method for screening of LS or around 15% of sporadic 
CRCs exhibiting MSI-H (Boland and Goel, 2010).
Unlike IHC staining which requires several tumor 
sections, MSI testing being a PCR based method, requires 
a small amount of tumor and preferably adjacent normal 
tissues DNA. On the other hand, in comparison with 
IHC analysis, MSI is an indirect method, hence unable to 
pinpoint the particular deficient/defective MMR protein(s) 
involved in the tumor development (Lindor et al., 2002). 
However, there are many studies conducted on either of 
these two tests preferences, but still no consensus reached 
in this regards. According to the preference of every center 
any one of these two tests hold as the first choice for MSI 
detection (Beamer et al., 2012). 
Apart from the recommended panels for MSI testing 
(Buhard et al., 2006), several studies performed in order 
to evaluate the feasibility of the more flexible MSI 
testing systems with reduced number of markers or even 
a single marker based detection system (Brennetot et 
al., 2005; Bouzourene et al., 2006; Deschoolmeester et 
al., 2008; Bianchi et al., 2009; Haghighi et al., 2010). 
In some studies CAT25 marker showed high sensitivity 
and specificity in comparison with standard NCI/ICG-
LYNCH SYNDROME marker panel (Findeisen et al., 
Najmeh Farahani et al
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2005; Bianchi et al., 2009). Using CAT25 alone or in 
combination with BAT26 marker is recommended by 
some authors as a suitable panel for MSI testing (Findeisen 
et al., 2005; Deschoolmeester et al., 2008).Although 
BAT-25 usefulness for determination of MSI status was 
questioned by some authors (Ichikawa et al., 2001), 
BAT-26 is regarded as superior in terms of sensitivity to 
identify MSI-H cancers (Xicola et al., 2007; Esemuede et 
al., 2010). Recently, Morandi et al studied 340 consecutive 
CRCs using three multiplexed polymerase chain reactions 
amplifying BAT25, BAT26, TGFBR2, MybT22, BAT40, 
MT1XT20, NR21, NR24, CAT25, D2S123, D5S346, 
D17S250, D18S58, CSF1PO, D7S820, and D18S51 
markers. MT1XT20 showed very high sensitivity (97.3%) 
comparable to BAT26 (97.5%) and CAT25 (97.1%). So 
we decided to conduct a comprehensive comparative study 
by employing both IHC for the main four MMR proteins 
and a standard PCR based five marker commercial kit 
(Promega MSI system covering BAT26, NR24, NR21, 
BAT25, MONO 27 markers). MT1XT20 standalone 
marker was also run parallel to two main MSI detection 
procedures and results were compared.
Eight patients (40%), out of 20 Amsterdam II selected 
CRC families, showed MSI-H status with Promega MSI 
testing system while using our in-house developed single 
marker MT1XT20 MSI testing protocol, 5 samples (25%) 
detected as MSI-H. However, based on IHC staining 7 
samples (35%) were regarded as MSI deficient. Although 
MT1XT20 showed superior results for MSI detection in 
Morandi et al study in Spanish population we couldn’t 
replicate the same in Iranian CRC patients. However 
using Promega MSI testing system, BAT26 was the most 
instable marker among the five markers included in this 
kit. So it may be concluded that in Persian population 
BAT26 could act well as standalone marker for MSI 
detection. Using single marker would simplify MSI 
testing considerably hence many more centers can execute 
this important test. Determination of MSI status in CRC 
patients with hereditary mode of transmission would be 
beneficial in confirmation of LS and then start to screen 
the whole family members in order to categorize them 
as MMR mutation carriers and non-carriers. In sporadic 
CRCs MSI detection would help as prognostic factor 
and essential for making right decision regarding adjuant 
chemotherapy regimen. 
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